KMT2A/MLL Antibody

ELISA: KMT2A/MLL Antibody [25300002]

Product Discontinued

KMT2A/MLL Antibody Summary

• Immunogen: This antibody is specific for the Middle Region of the target protein.
• Specificity: This product is specific for Human KMT2A/MLL
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: KMT2A
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:250-1:2000
• Application Notes: This antibody is useful in ELISA and Immunohistochemistry-Paraffin.

Reactivity Notes

Human.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: 20mM Potassium Phosphate (pH 7.0) and 0.15M NaCl
• Preservative: No Preservative
• Purity: Immunogen affinity purified

Notes

Manufactured by SDIX's proprietary Genomic Antibody Technology™. GAT FAQs.

Alternate Names for KMT2A/MLL Antibody

• ALL1
• ALL-1MLL/GAS7
• CXXC7TET1-MLL
• CXXC-type zinc finger protein 7
• EC 2.1.1.43
• HRXFLJ11783
• HTRX
• HTRX1MLL-AF4 der(11) fusion protein
• KMT2ACDK6/MLL fusion protein
• Lysine N-methyltransferase 2A
• MLL/GAS7 fusion protein
• MLL/GMPS fusion protein
• MLL1
• MLL1A
• myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog)
• myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)
• Trithorax-like protein
• TRX1histone-lysine N-methyltransferase MLL
• Zinc finger protein HRX

Background

The KMT2A/MLL gene encodes a DNA-binding protein that methylates histone H3 (see MIM 601128) lys4 (H3K4) and positively regulates expression of target genes, including multiple HOX genes (see MIM 142980). KMT2A/MLL is a frequent target for recurrent translocations in acute leukemias that may be characterized as acute myeloid leukemia (AML; MIM 601626), acute lymphoblastic leukemia (ALL), or mixed lineage (biphenotypic) leukemia (MLL). Leukemias with translocations involving MLL possess unique clinical and biologic characteristics and are often associated with poor prognosis. MLL rearrangements are found in more than 70% of infant leukemias, whether the immunophenotype is more consistent with ALL or AML6, but are less frequent in leukemias from older children. KMT2A/MLL translocations are also found in approximately 10% of AMLs in adults, as well as in therapy-related leukemias, most often characterized as AML, that develop in patients previously treated with topoisomerase II inhibitors for other malignancies. More than 50 different KMT2A/MLL fusion partners have been identified. Leukemogenic KMT2A/MLL translocations encode KMT2A/MLL fusion proteins that have lost H3K4 methyltransferase activity. A key feature of KMT2A/MLL fusion proteins is their ability to efficiently transform hematopoietic cells into leukemia stem cells (Krivtsov and Armstrong, 2007 [PubMed 17957188]).[supplied by OMIM]

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for KMT2A/MLL Antibody (25300002)(2)

Publications using 25300002

• Garrison C, Lastwika K, Zhang Y et al. Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections With Obesity J Proteome Res. 2017-01-06 [PMID: 27769113] (MiAr)
  
  Details:
  Analysis is performed on plasma proteomic data to identify how obesity can alter pathways and to highlight the risk factor for disease in subjects with a high body mass index.
• Rho JH, Lampe PD. High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays J Proteome Res. 2013-05-03 [PMID: 23541305] (MiAr)
  
  Details:
  A novel method using antibody microarrays is used to detect autoantibody-antigen complexes that can potentially be useful for detection and characterization of diseases.

Bioinformatics

• Gene Symbol: KMT2A
• Uniprot:
  • Q03164(Human)